SecBot SecBot

HRTX

HERON THERAPEUTICS, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0000818033 Biotech & Drug Discovery
$0.3021 +0.00 (+0.70%)
Oct 26 4:00 PM ET · prev $0.3000
Market cap
$56.2M
Micro cap
Consensus
Sell
0% Buy or better · 7 analysts
Median target
$7.00
+2217% · range $5.00–9.00
Next earnings
Nov 10
in 15 days · EPS est. −$0.03
1 year
−74.4%
from $1.18 · Oct 27
30 days
+4.2%
from $0.2900
52-week range
$0.2700–1.49
−80% from high · low Sep 21
Avg volume 20D
2.47M
shares / day
Short interest
46.02M
≈24.2% of shares · +6.1%
Days to cover
17.3
at average volume
Insider net
$0
no open-market trades · since Jan 30
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BEARISH 2 reports · 90 days
Balance 2 bearish · 0 bullish oldest → newest, height = score
Avg score ·High conf. 2/2 ·Next Earnings date, Nov 10, 2026
Strongest BEARISH Heron Therapeutics reported Q2 2026 revenue of $37.7M (missed consensus of $42.2M by 10.7%) and GAAP EPS of…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since Jan 30. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 23 added (0 new), 15 trimmed or exited.

  • AnalystsBEARISH

    0 of 7 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.020 → −$0.025 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest +6.1% to 46.02M shares. 17.3 days to cover, ≈24.2% of shares.

  • TrendRANGE

    8% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
MILLENNIUM MANAGEMENT LLCTRIM4,070,101$1.7M
UBS Group AGADD2,997,073$1.3M
GOLDMAN SACHS GROUP INCADD1,329,754$567.5K
PANAGORA ASSET MANAGEMENT INCADD1,281,796$547.1K
Qube Research & Technologies LtdDOUBLED1,021,092$435.8K
Caption Management, LLCDOUBLED1,000,000$426.8K
NEW YORK STATE COMMON RETIREMENT FUNDTRIM694,165$296.3K
ALLIANCEBERNSTEIN L.P.ADD299,910$240.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

7 analysts
Sell 0% rate it Buy or better
Strong Buy0Buy0Hold4Sell1Strong Sell2
12-month targets · 3 analysts

Price is below the lowest target. Median implies +2217%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Aug 11, 2026HC Wainwright & Co.
DOWNGRADE
DOWNGRADENeutral
Jun 3, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jun 3, 2026Needham
DOWNGRADE
DOWNGRADEHold

Insider ledger

Form 4
$0
open-market buys or sells · since Jan 30
DateInsiderTypeValue
Oct 19, 2026
Forbes William P
EVP, Chief Development Officer
EXERCISE3,874 sh
Oct 19, 2026
Forbes William P
EVP, Chief Development Officer
TAX W/H$396.72
Oct 19, 2026
Duarte Ira
EVP, Chief Financial Officer
EXERCISE3,874 sh
Oct 19, 2026
Duarte Ira
EVP, Chief Financial Officer
TAX W/H$396.72
Oct 19, 2026
Collard Craig A
Chief Executive Officer
EXERCISE13,797 sh
Oct 19, 2026
Collard Craig A
Chief Executive Officer
TAX W/H$1.2K
Aug 6, 2026
Hensley Mark Earl
Chief Operating Officer
EXERCISE31,250 sh
Aug 6, 2026
Hensley Mark Earl
Chief Operating Officer
TAX W/H$4.4K

Earnings setup

Estimates
Nov 10
reports in 15 days
−$0.03
EPS estimate, this quarter
−25%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.03-$0.03–-$0.02-25.0%$37.5M
Next Q-$0.03-$0.03–-$0.03-200.0%$38.4M
Current FY-$0.13-$0.14–-$0.12-44.4%$148.3M
Next FY-$0.11-$0.12–-$0.10—$145.9M

Short side

FINRA· Sep 30, 2026
46,021,379
shares short
+6.1%
vs prior settlement
17.3
days to cover
≈24.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 19, 2026 Insider
Forbes William P acquired via exercise 3,874 shares
EVP, Chief Development Officer
Oct 19, 2026 Insider
Forbes William P surrendered for taxes 1,102 shares
EVP, Chief Development Officer @ $0.3600 ($396.72)
Oct 19, 2026 Insider
Duarte Ira acquired via exercise 3,874 shares
EVP, Chief Financial Officer
Aug 10, 2026 SEC
Heron Therapeutics withdrew full-year 2026 guidance and announced a strategic alternatives review, citing a June 2026…
8-K — Impact 7/10
Aug 10, 2026 SEC
Heron Therapeutics reported Q2 2026 revenue of $37.7M (missed consensus of $42.2M by 10.7%) and GAAP EPS of -$0.03…
PRESS-RELEASE — Impact 7/10
Aug 10, 2026 Earnings
Heron Therapeutics Announces Second Quarter 2026 Financial Results
– Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF ® net revenue
Jun 30, 2026 Inst.
MILLENNIUM MANAGEMENT LLC — TRIM
4,070,101 shares ($1.7M)
Jun 30, 2026 Inst.
UBS Group AG — ADD
2,997,073 shares ($1.3M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
HRTX Q3 2026 Earnings Scheduled — 2026-11-10
Recent
Aug 10, 2026
Earnings
Heron Therapeutics Announces Second Quarter 2026 Financial Results
– Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF ® net revenue grew 35% and APONVIE ® net revenue grew 74%…
Aug 10, 2026
Earnings date
HRTX Q2 2026 Earnings Scheduled — 2026-08-10
Jul 17, 2026
Clinical Trial
HTX-011 for Post-bunionectomy Analgesia
Phase 2 · COMPLETED
Jun 9, 2026
Clinical Trial
Dose-Escalation Study of HTX-034 Following Bunionectomy
Phase 2 · COMPLETED
Jun 4, 2026
Clinical Trial
Study of Post-Herniorrhaphy Non-opioid MMA Regimens
Phase 3 · COMPLETED

SecBot reports

10 filings · 0 bullish · 6 bearish · 1 mixed · 3 neutral
All HRTX filing & press-release reports (10)